Backed by a multi center randomized study, iNAP showed a 52% responder rate with sustained benefits over 28 days—proving that comfort and clinical impact can go hand in hand. Discover how this mask-free therapy is reshaping moderate-to-severe OSA management.
Blog Category
Multicenter First Night Cross-Over Study - iNAP
By taevas on 24th Nov 2025
Experience
Innovation
Firsthand
Our innovation targets the deepest challenges in healthcare, from patient discomfort to diagnostic uncertainty. We deliver breakthrough solutions that improve compliance, provide swift, accurate diagnoses, and create pathways to healing that never existed before.
Subscribe to
Taevas Perspectives
Insights on healthcare innovations, market trends & health care advancements.